Scribe Therapeutics

Scribe is a molecular engineering company using its CRISPR-based XE technology to develop precise in vivo gene edits for treating genetic diseases.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2026
Stage of Initial Investment
Series B
Initial Investment Year
2021
Sctibe Tx Hover Image